0000000000911547

AUTHOR

Johannes Waltenberger

showing 2 related works from this author

Five-Year Results of the Bioflow-III Registry:Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent

2018

Abstract Purpose We aimed to assess long-term safety and performance of the Orsiro sirolimus-eluting coronary stent with biodegradable polymer in a large unselected population and in pre-specified subgroups. Methods BIOFLOW-III is a prospective, multicenter, international, observational registry with follow-up visits scheduled at 6 and 12 months, and at 3 and 5 years ( NCT01553526 ). Results 1356 patients with 1738 lesions were enrolled. Of those, 392 (28.9%) declined to participate in the study extension from 18 months to 5 years, 37 (2.7%) withdrew consent, and 89 (6.6%) were lost to follow-up. At 5-years, Kaplan-Meier estimates of target lesion failure, defined as a composite of cardiac …

MaleTarget lesionTime Factorsmedicine.medical_treatmentMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematology0302 clinical medicineRecurrenceRisk FactorsAbsorbable ImplantsBiodegradable polymerProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionAngioplasty Balloon Coronaryeducation.field_of_studyDiabetesDrug-Eluting StentsGeneral MedicineCoronary artery stenosisMiddle AgedTreatment OutcomeDrug-eluting stentFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyPolyestersPopulationHybrid stentProsthesis Design03 medical and health sciencesDiabetes mellitusCoronary stentmedicineHumanseducationAgedSirolimusbusiness.industryCoronary ThrombosisStentCardiovascular Agentsmedicine.diseaseConfidence intervalSurgeryCoronary OcclusionChronic DiseaseDrug-eluting stentbusiness
researchProduct

Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

2019

Gislason, Gunnar H/0000-0002-0548-402X; Malynovsky, Yaroslav V/0000-0002-9118-1104; Bhatt, Deepak L./0000-0002-1278-6245; Nikolaev, Konstantin/0000-0003-4601-6203; Sherwood, Matthew/0000-0002-4305-5883; Chumakova, Galina A/0000-0002-2810-6531; Raffel, Owen C/0000-0001-5470-7050; Leonardi, Sergio/0000-0002-4800-6132; Tse, Hung Fat/0000-0002-9578-7808; Reshetko, Olga/0000-0003-3107-7636; Pereira, Helder/0000-0001-8656-4883; Racca, Vittorio/0000-0002-4465-3789; Podoleanu, Cristian/0000-0001-9987-2519; Ersanli, Murat/0000-0003-1847-3087; Muenzel, Thomas/0000-0001-5503-4150; Sandhu, Manjinder/0000-0003-2538-2079; Taskinen, Marja-Riitta/0000-0002-6229-3588; bastos, jose/0000-0002-9526-3123; Manak…

MaleBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.Cardiac & Cardiovascular SystemsMyocardial InfarctionUNIVERSAL DEFINITION030204 cardiovascular system & hematologyTHERAPYDISEASEchemistry.chemical_compound0302 clinical medicineCardiac and Cardiovascular Systems030212 general & internal medicineMyocardial infarctionProspective Studies1102 Cardiorespiratory Medicine and HaematologyOxygen supplyKardiologiBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.CHOLESTEROLMiddle AgedMI typesCardiologyLDL Cholesterol LipoproteinsFemaleCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemedicine.medical_specialty610ODYSSEY OUTCOMES InvestigatorsAntibodies Monoclonal HumanizedCLASSIFICATION03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansddc:610Alirocumab ; MI types ; Mortality ; PreventionMortalityMETAANALYSISAlirocumabAgedScience & TechnologyTask forceCholesterolbusiness.industryEVOLOCUMABPrevention1103 Clinical SciencesCholesterol LDLmedicine.diseaseEvolocumabchemistryCardiovascular System & HematologyCardiovascular System & CardiologyHuman medicinebusinessAlirocumab
researchProduct